July 8, 2020
Revolution Medicines Announces Pricing of $156.0 Million Public Offering of Common Stock
July 6, 2020
Revolution Medicines Announces Proposed Public Offering of Common Stock
June 30, 2020
Revolution Medicines Reports New Application of Tri-Complex Modality for “Undruggable” Protein Targets and Announces License to Ginkgo Bioworks to Explore Potential Use Against Novel Coronavirus
June 22, 2020
Revolution Medicines Provides Research and Development Update for its Portfolio of Novel Targeted Cancer Therapies
June 22, 2020
Revolution Medicines Announces Dosing of First Patient in Clinical Study of RMC-4630 (SAR442720) Combined with PD-1 Inhibitor
June 18, 2020
Revolution Medicines Appoints Eric T. Schmidt, Ph.D. and Peter Svennilson to its Board of Directors
June 9, 2020
Revolution Medicines Announces Dosing of First Patient in Phase 1b Combination Study of RMC-4630 and AMG 510
May 19, 2020
Revolution Medicines Announces Four Presentations at the 2020 American Association for Cancer Research Virtual Annual Meeting II
May 14, 2020
Revolution Medicines Reports First Quarter 2020 Financial Results and Continued Corporate Progress
April 29, 2020
Revolution Medicines Announces Publication of Scientific Paper Describing Anti-Tumor Immunity Induced by SHP2 Inhibitor in Preclinical Cancer Models